JP2017534591A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534591A5
JP2017534591A5 JP2017516735A JP2017516735A JP2017534591A5 JP 2017534591 A5 JP2017534591 A5 JP 2017534591A5 JP 2017516735 A JP2017516735 A JP 2017516735A JP 2017516735 A JP2017516735 A JP 2017516735A JP 2017534591 A5 JP2017534591 A5 JP 2017534591A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
aryl
heteroaryl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017516735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534591A (ja
JP6770511B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/052611 external-priority patent/WO2016053855A1/en
Publication of JP2017534591A publication Critical patent/JP2017534591A/ja
Publication of JP2017534591A5 publication Critical patent/JP2017534591A5/ja
Application granted granted Critical
Publication of JP6770511B2 publication Critical patent/JP6770511B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017516735A 2014-09-29 2015-09-28 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター Expired - Fee Related JP6770511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462056946P 2014-09-29 2014-09-29
US62/056,946 2014-09-29
PCT/US2015/052611 WO2016053855A1 (en) 2014-09-29 2015-09-28 Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders

Publications (3)

Publication Number Publication Date
JP2017534591A JP2017534591A (ja) 2017-11-24
JP2017534591A5 true JP2017534591A5 (enExample) 2018-10-25
JP6770511B2 JP6770511B2 (ja) 2020-10-14

Family

ID=55631308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516735A Expired - Fee Related JP6770511B2 (ja) 2014-09-29 2015-09-28 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター

Country Status (13)

Country Link
US (2) US10323029B2 (enExample)
EP (1) EP3209732B1 (enExample)
JP (1) JP6770511B2 (enExample)
KR (1) KR102307037B1 (enExample)
CN (1) CN107001806B (enExample)
AU (1) AU2015324163B2 (enExample)
CA (1) CA2962922C (enExample)
EA (1) EA031503B1 (enExample)
ES (1) ES2895174T3 (enExample)
IL (1) IL251387B (enExample)
SG (1) SG11201702483QA (enExample)
WO (1) WO2016053855A1 (enExample)
ZA (1) ZA201702403B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6770511B2 (ja) 2014-09-29 2020-10-14 ザ スクリプス リサーチ インスティテュート 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター
EP3419973B1 (en) * 2016-02-24 2020-04-08 Acesion Pharma ApS Novel potassium channel inhibitors
US11049009B2 (en) * 2017-06-12 2021-06-29 Western Digital Technologies, Inc. Identifying memory block write endurance using machine learning
JP2020535147A (ja) * 2017-09-29 2020-12-03 ノバルティス アーゲー シポニモドの投与レジメン
CN112469697B (zh) * 2018-07-11 2025-02-14 鲁贝多生命科学公司 抗衰老组合物及其用途
KR102218280B1 (ko) * 2019-01-30 2021-02-22 주식회사 엑세쏘바이오파마 P1p 유도체의 패혈증 치료제 용도
CN114269340A (zh) * 2019-05-03 2022-04-01 普拉克西斯精密药物股份有限公司 Kcnt1抑制剂和使用方法
CN113200971B (zh) * 2021-05-14 2022-06-28 济南大学 一类具有芳香基哌嗪结构的吲哚恶二唑衍生物的合成和应用
MX2023013690A (es) * 2021-05-17 2024-01-30 Hk Inno N Corp Derivado de benzamida, metodo para preparar el mismo, y composicion farmaceutica para la prevencion o tratamiento del cancer que contiene el mismo como ingrediente activo.
WO2025176104A1 (en) 2024-02-19 2025-08-28 Ono Pharmaceutical Co., Ltd. Heterocyclic derivatives having s1p3 receptor antagonistic activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2085736A (en) * 1933-12-06 1937-07-06 Du Pont Compounds of the triphenylmethane series
US3217012A (en) * 1960-10-26 1965-11-09 Purdue Research Foundation Substituted pyridines, process for and new compositions
US3916000A (en) * 1971-07-21 1975-10-28 Commw Scient Ind Res Org Alkylation process
EP0355864A3 (en) * 1984-03-15 1991-09-18 Wako Pure Chemical Industries, Ltd. Method of quantitatively measuring an oxidative substance by using triphenyl methane type leuco compounds as coloring matter
US6028103A (en) 1994-09-16 2000-02-22 Children's Medical Center Corporation Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
US20020156301A1 (en) * 1997-06-17 2002-10-24 Sumitomo Chemical Co., Ltd. Triphenylmethane derivatives and use thereof
JP4709488B2 (ja) * 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
EA011507B1 (ru) * 2003-08-27 2009-04-28 Зентива А.С. Способ получения калиевой соли лосартана
US7888376B2 (en) * 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101528699A (zh) * 2005-11-23 2009-09-09 布里斯托尔—迈尔斯斯奎布公司 杂环胆固醇酯转运蛋白抑制剂
BRPI0715872A2 (pt) * 2006-08-23 2014-08-26 Wyeth Corp Composto; composição farmacêutica; método de preparação do composto; composto preparado pelo método; e método de tratamento de um transtorno em um mamífero necessitado
CN103896831A (zh) * 2007-08-27 2014-07-02 Abbvie德国有限责任两合公司 4-(4-吡啶基)-苯甲酰胺及其作为rock活性调节剂的应用
AU2009225869B2 (en) * 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
CA2724426A1 (en) * 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010014948A1 (en) * 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
JP2013028538A (ja) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
RU2013129483A (ru) * 2010-12-03 2015-01-10 Аллерган, Инк. Новые фениловые производные оксадиазола в качестве модуляторов рецептора сфингозин 1-фосфата (s1p)
WO2012074703A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
EP2646027B1 (en) * 2010-12-03 2014-10-15 Allergan, Inc. Novel pyridine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
PH12013502611A1 (en) * 2011-06-24 2014-04-28 Amgen Inc Trpm8 antagonists and their use in treatments
DE202013011832U1 (de) * 2012-04-11 2014-07-25 Fluoron Gmbh Färbemittel
US9410058B2 (en) 2014-04-10 2016-08-09 United States Gypsum Company Compositions and methods for water-resistant gypsum fiber products
JP6770511B2 (ja) 2014-09-29 2020-10-14 ザ スクリプス リサーチ インスティテュート 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター

Similar Documents

Publication Publication Date Title
JP2017534591A5 (enExample)
TWI400234B (zh) 作為組織胺ｈ4受體調節劑之苯并咪唑-２-基嘧啶類及吡類
JP2020531422A5 (enExample)
JP2013523802A5 (enExample)
JP2018534301A5 (enExample)
JP2012507522A5 (enExample)
JP2016515096A5 (enExample)
JP2020510015A5 (enExample)
JP2015532287A5 (enExample)
JP2016516699A5 (enExample)
JP2018534348A5 (enExample)
JP2016530259A5 (enExample)
JPWO2022016070A5 (enExample)
JP2011523412A5 (enExample)
JP2016500111A5 (enExample)
JP2016529306A5 (enExample)
JP2015526411A5 (enExample)
JP7644823B2 (ja) ピリドン多環縮合環系誘導体及びその使用
JP2016511753A5 (enExample)
JP2017506666A5 (enExample)
JP2014097964A5 (enExample)
JP2018528182A (ja) ６−（アリールまたはヘテロアリール）−１，３，５−トリアジン−２，４−ジオール及び６−（アリールまたはヘテロアリール）−１，３，５−トリアジン−２，４−ジアミンを調製する方法
JP2019505529A5 (enExample)
JP2015509075A5 (enExample)
JP2017537886A5 (enExample)